Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer
Sponsor: NCIC Clinical Trials Group
This PHASE2 trial investigates Fallopian Tube Cancer and Ovarian Cancer and is currently completed. NCIC Clinical Trials Group leads this study, which shows 8 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Apr 2020 — May 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCIC Clinical Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .